Humalog
These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG. HUMALOG (insulin lispro injection), for subcutaneous or intravenous use Initial U.S. Approval: 1996
1cfbd95f-d848-43b9-9a65-d3ce1cf782c7
HUMAN PRESCRIPTION DRUG LABEL
Aug 13, 2019
REMEDYREPACK INC.
DUNS: 829572556
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Insulin lispro
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (9)
Drug Labeling Information
INFORMATION FOR PATIENTS SECTION
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
17.1 Never Share a HUMALOG KwikPen, Cartridge, Reusable Pen Compatible with
Lilly 3 mL Cartridges, or Syringe Between Patients
Advise patients that they must never share a HUMALOG KwikPen, cartridge, or reusable pen compatible with Lilly 3 mL cartridges with another person, even if the needle is changed. Advise patients using HUMALOG vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
17.2 Hypoglycemia
Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of HUMALOG therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia.
Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see Warnings and Precautions ( 5.3)] .
17.3 Hypersensitivity Reactions
Advise patients that hypersensitivity reactions have occurred with HUMALOG. Inform patients on the symptoms of hypersensitivity reactions [see Warnings and Precautions ( 5.5)] .
17.4 Medication Errors
Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products.
Inform patients that HUMALOG U-200 contains 2 times as much insulin in 1 mL as HUMALOG U-100.
Inform patients that the HUMALOG U-200 KwikPen dose window shows the number of units of HUMALOG U-200 to be injected and that no dose conversion is required.
Instruct patients to NOT transfer HUMALOG U-200 from the HUMALOG KwikPen to a syringe. The markings on the syringe will not measure the dose correctly and this can result in overdosage and severe hypoglycemia.
17.5 Administration Instruction for HUMALOG U-200
Instruct patients to NOT mix HUMALOG U-200 with any other insulin.
17.6 Women of Reproductive Potential
Advise females of reproductive potential with diabetes to inform their doctor if they are pregnant or are contemplating pregnancy [see Use in Specific Populations ( 8.1)] .
17.7 Instructions For Patients Using Continuous Subcutaneous Insulin Pumps
Patients using external pump infusion therapy should be trained appropriately.
The following insulin pumps have been tested in HUMALOG clinical trials conducted by Eli Lilly and Company.
- Disetronic ® H-Tron ® plus V100, D-Tron ® and D-Tronplus ® with Disetronic Rapid infusion sets 2
- MiniMed ® Models 506, 507 and 508 and Polyfin ® infusion sets 3
HUMALOG is recommended for use in pump systems suitable for insulin infusion such as MiniMed, Disetronic, and other equivalent pumps. Before using HUMALOG in a pump system, read the pump label to make sure the pump is indicated for continuous delivery of fast-acting insulin. HUMALOG is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Please see recommended reservoir and infusion sets in the pump manual. Do not use HUMALOG U-200 in an external insulin pump.
To avoid insulin degradation, infusion set occlusion, and loss of the preservative (metacresol), insulin in the reservoir should be replaced at least every 7 days; infusion sets and infusion set insertion sites should be changed at least every 3 days.
Insulin exposed to temperatures higher than 98.6°F (37°C) should be discarded. The temperature of the insulin may exceed ambient temperature when the pump housing, cover, tubing or sport case is exposed to sunlight or radiant heat. Infusion sites that are erythematous, pruritic, or thickened should be reported to the healthcare professional, and a new site selected because continued infusion may increase the skin reaction or alter the absorption of HUMALOG.
Pump or infusion set malfunctions or insulin degradation can lead to rapid hyperglycemia and ketosis. This is especially pertinent for rapid acting insulin analogs that are more rapidly absorbed through skin and have a shorter duration of action. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Problems include pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. Less commonly, hypoglycemia from pump malfunction may occur. If these problems cannot be promptly corrected, patients should resume therapy with subcutaneous insulin injection and contact their healthcare professionals [see Dosage and Administration ( 2.2) and How Supplied/Storage and Handling ( 16.2)] .
1 3 mL cartridge is for use in Eli Lilly and Company's HumaPen ® Luxura ® HD
insulin delivery device, and Disetronic
D-TRON ® and D-TRON ® Plus pumps.
Humalog ®, Humalog KwikPen ®, Humalog ® Junior KwikPen ®, HumaPen ®, HumaPen ® Luxura ® and HumaPen ® Luxura ® HD are trademarks of Eli Lilly and Company.
2 Disetronic ®, H-Tron ®, D-Tron ®, and D-Tronplus ® are registered trademarks of Roche Diagnostics GmbH.
3 MiniMed ® and Polyfin ® are registered trademarks of MiniMed, Inc.
Other product and company names may be the trademarks of their respective owners.
Literature revised November 2018
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
www.humalog.com
Copyright © 1996, 2018, Eli Lilly and Company. All rights reserved.
LOG-0007-USPI-20181101
SPL PATIENT PACKAGE INSERT SECTION
Patient Information |
Do not share your HUMALOG KwikPen with other people, even if the needle has
been changed. You may give other people a serious infection, or get a serious
infection from them.
|
Who should not take HUMALOG?
|
What should I tell my healthcare provider before using HUMALOG?
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements. |
How should I use HUMALOG KwikPen?
Keep HUMALOG KwikPen and all medicines out of reach of children. |
Your dose of HUMALOG may need to change because of a:
|
What should I avoid while using HUMALOG KwikPen?
|
What are the possible side effects of HUMALOG? *low blood sugar (hypoglycemia). Signs and symptoms of low blood sugar may include: * dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood changes, hunger. *severe allergic reaction (whole body reaction). Get medical help right away, if you have any of these signs or symptoms of a severe allergic reaction: * a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating. *low potassium in your blood (hypokalemia). *heart failure. Taking certain diabetes pills called TZDs (thiazolidinediones) with HUMALOG may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with HUMALOG. Your healthcare provider should monitor you closely while you are taking TZDs with HUMALOG. Tell your healthcare provider if you have any new or worse symptoms of heart failure including: * shortness of breath, swelling of your ankles or feet, sudden weight gain Treatment with TZDs and HUMALOG may need to be adjusted or stopped by your
healthcare provider if you have new or worse heart failure.
The most common side effects of HUMALOG include:
These are not all of the possible side effects from HUMALOG. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
General Information about the safe and effective use of HUMALOG KwikPen. |
What are the ingredients in HUMALOG U-200? Humalog ® and Humalog KwikPen ® are registered trademarks of Eli Lilly and
Company. For more information, go to www.humalog.com. |
This Patient Information has been approved by the U.S. Food and Drug Administration
LOG200-0001-PPI-20150526
INSTRUCTIONS FOR USE SECTION
Instructions for Use
HUMALOG**®Junior KwikPen®**
insulin lispro injection
100 units/mL, 3 mL pen
Read the Instructions for Use before you start taking HUMALOG and each time you get another HUMALOG ® Junior KwikPen ®. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your HUMALOG Junior KwikPen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
HUMALOG Junior KwikPen (“Pen”) is a disposable prefilled pen containing 300 units of HUMALOG.
People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.
How to recognize your HUMALOG Junior KwikPen:
- You can give yourself more than 1 dose from the Pen.
- Each turn of the Dose Knob dials 0.5 (½) unit of insulin. You can give from 0.5 (½) to 30 units in a single injection.
- If your dose is more than 30 units, you will need to give yourself more than 1 injection.
- The Plunger only moves a little with each injection, and you may not notice that it moves. The Plunger will only reach the end of the cartridge when you have used all 300 units in the Pen.
Supplies needed to give your injection:
* Pen color: Blue
* Dose Knob: Blue, with raised ridges on end and side
* Label: White with an orange color bar and orange-to-yellow color band
Preparing your Pen
* HUMALOG Junior KwikPen
* KwikPen compatible Needle (BD [Becton, Dickinson and Company] Pen Needles recommended)
* Alcohol swab
* Gauze
Priming your Pen
Prime before each injection.
Step 6:
|
Step 7:
|
Step 8:
|
Selecting your dose
LOGJRKP-0002-IFU-20181101
Giving your injection
|